Stifel Downgrades Auspex Pharmaceuticals (ASPX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Teva Reinforces Leadership Position in CNS with Acquisition of Auspex
March 30, 2015 7:00 AM EDTExpected to strengthen Teva's core CNS franchise, establish Tevas leadership in underserved movement disorders space, provide compelling new treatment options for patients in need, and enhance Tevas long-term revenue and earnings growth
All-Cash Transaction with Enterprise Value of $3.2 Billion
JERUSALEM & LA JOLLA, Calif.--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), today announced that they have entered into a definitive merger agreement under which Teva will commence a tender offer for... More
